Combination Treatments of Plasma Exchange and Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Clinical Trial in China
Table 1
Patient’s characteristics and baseline clinical features.
Parameters
Control ()
UC-MSC ()
PE ()
PE + UC-MSC ()
Sex
Male
28 (93.33)
29 (96.67)
27 (90.00)
20 (100.00)
0.308
Female
2 (6.67)
1 (3.33)
3 (10.00)
0 (0.00)
Age, year
44.97 ± 11.83
40.67 ± 9.89
40.87 ± 12.17
42.00 ± 6.55
0.407
Complications
19 (63.33)
16 (53.33)
21 (70.00)
11 (55.00)
0.542
Peritonitis
15 (50.00)
12 (40.00)
14 (46.67)
9 (45.00)
0.889
Pneumonia
1 (3.33)
6 (20.00)
2 (6.67)
3 (15.00)
0.144
Enteritis
2 (6.67)
3 (10.00)
3 (10.00)
2 (10.00)
0.958
Gastrointestinal bleeding
3 (10.00)
0 (0.00)
0 (0.00)
0 (0.00)
0.046
Hepatic encephalopathy
11 (36.67)
4 (13.33)
8 (26.67)
5 (25.00)
0.210
Hepatorenal syndrome
2 (6.67)
0 (0.00)
0 (0.00)
2 (10.00)
0.083
WBC, 109/L
7.75 ± 3.20
5.87 ± 2.22
7.34 ± 3.13
7.88 ± 3.46
0.075
N%
67.94 ± 11.83
59.64 ± 12.21
61.21 ± 12.80
64.07 ± 10.12
0.042
RBC, 1012/L
3.55 ± 0.59
3.35 ± 0.70
3.62 ± 0.97
3.82 ± 0.74
0.268
Hemoglobin, g/L
113.47 ± 18.28
107.63 ± 20.34
113.63 ± 23.80
113.90 ± 18.65
0.614
Platelet, 109/L
109.33 ± 66.76
100.53 ± 52.89
90.93 ± 41.98
122.80 ± 97.38
0.306
AST, U/L
260.10 ± 236.92
245.10 ± 385.06
205.13 ± 213.37
199.65 ± 188.63
0.139
ALT, U/L
373.50 ± 492.01
289.30 ± 594.25
234.57 ± 238.56
168.45 ± 149.75
0.067
Albumin, g/L
32.72 ± 3.76
34.57 ± 4.24
35.44 ± 3.79
35.60 ± 4.70
0.023
Cholinesterase, U/L
3548.40 ± 1786.64
3684.93 ± 1365.60
4068.77 ± 1070.67
4075.80 ± 1136.24
0.245
TBIL, μmol/L
468.44 ± 139.43
455.78 ± 117.61
501.81 ± 135.53
542.86 ± 149.65
0.138
Creatinine, μmol/L
85.04 ± 44.69
66.07 ± 18.62
76.65 ± 24.80
79.37 ± 36.90
0.096
Prothrombin time, sec.
28.99 ± 8.49
29.53 ± 6.72
32.33 ± 8.00
27.42 ± 4.32
0.097
Prothrombin activity, %
30.13 ± 7.26
27.57 ± 6.95
26.27 ± 7.48
31.40 ± 8.86
0.096
INR
2.82 ± 1.17
2.80 ± 0.83
3.22 ± 1.06
2.59 ± 0.54
0.128
MELD score
28.73 ± 4.91
26.73 ± 4.17
29.83 ± 4.93
28.10 ± 4.67
0.092
Treatment-related complications
Fever
0.528
1 episode
—
8 (26.67)
—
5 (25.00)
2 episodes
—
1 (3.33)
—
1 (5.00)
3 episodes
—
2 (6.67)
—
0
Allergic reaction
0.537
1 episode
—
—
7 (23.33)
6 (30.00)
2 episodes
—
—
1 (3.33)
0
Bleeding at the catheter insertion site
—
—
4 (13.33)
1 (5.00)
0.636
UC-MSC, umbilical cord-derived mesenchymal stem cells; PE, plasma exchange; WBC, white blood cells; RBC, red blood cells; AST, aspartate aminotransferase; ALT, alanine transaminase; TBIL, total bilirubin; INR, international normalized ratio; MELD, model for end-stage liver disease.
